# Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

> **NCT06126380** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Eledon Pharmaceuticals** · enrollment: 132 (estimated)

## Conditions studied

- Kidney Transplant Rejection

## Interventions

- **DRUG:** AT-1501
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT06126380
- **Lead sponsor:** Eledon Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-10-25
- **Primary completion:** 2029-12
- **Final completion:** 2029-12
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06126380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06126380, "Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT06126380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*